SCHEMBL1370060

SCHEMBL1370060

CNS(=O)(=O)c1ccc(C)c(Br)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.53
GAA P10253 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.50
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
CA9 Q16790 3/20 0.47
CA12 O43570 2/20 0.47
CA3 P07451 2/20 0.47
CA4 P22748 2/20 0.47
CA6 P23280 2/20 0.47
CA5A P35218 2/20 0.47
CA7 P43166 2/20 0.47
CA13 Q8N1Q1 2/20 0.47
CA14 Q9ULX7 2/20 0.47
CA5B Q9Y2D0 2/20 0.47
TAS2R14 Q9NYV8 1/20 0.46
HTT P42858 1/20 0.46
ALDH1A1 P00352 2/20 0.44
VCAM1 P19320 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710212 0.85 LMNA (0.59) LMNASMN1; SMN2GAAL3MBTL1CA1
SCHEMBL10154281 0.82 LMNA (0.71) LMNASMN1; SMN2GAAL3MBTL1CA1
SCHEMBL27438026 0.81 LMNA (0.50) LMNASMN1; SMN2GAAL3MBTL1CA1
SCHEMBL1369496 0.80 LMNA (0.53) LMNASMN1; SMN2ALDH1A1MAPK1
SCHEMBL1368170 0.80 ALDH1A1 (0.49) LMNAALDH1A1PNMT
SCHEMBL6782609 0.79 ALDH1A1 (0.48) LMNASMN1; SMN2GAACA1CA2
SCHEMBL20767241 0.79 CA1 (0.63) LMNASMN1; SMN2GAAL3MBTL1CA1
SCHEMBL20779633 0.79 CA1 (0.50) LMNASMN1; SMN2GAAL3MBTL1CA1
SCHEMBL29909892 0.79 CA1 (0.63) LMNASMN1; SMN2GAAL3MBTL1CA1
SCHEMBL18578538 0.79 VCAM1 (0.58) LMNASMN1; SMN2GAAL3MBTL1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101863539-B Methods and articles for maintaining hydantoinylated polymers in a biocidally active state VANSON HALOSOURCE INC 2015-02-18 CN disclosed
US-8722656-B2 Cephalosporins useful as antibacterial agents ZOETIS LLC (US) 2014-05-13 US disclosed
EP-2705044-A1 NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS ZOETIS LLC (US) 2014-03-12 EP disclosed
WO-2012150520-A1 NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2012-11-08 WO disclosed
US-20120283237-A1 NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2012-11-08 US disclosed
US-8273769-B2 Phenoxy acetic acid derivatives MERCK SERONO SA (CH) 2012-09-25 US disclosed
US-20110288066-A1 PHENOXY ACETIC ACID DERIVATIVES MERCK SERONO S.A. (CH) 2011-11-24 US disclosed
EP-1678078-A1 METHODS AND ARTICLES FOR MAINTAINING HYDANTOINYLATED POLYMERS IN A BIOCIDALLY ACTIVE STATE Vanson Halosource, Inc. (US) 2006-07-12 EP disclosed
WO-2005033004-A1 METHODS AND ARTICLES FOR MAINTAINING HYDANTOINYLATED POLYMERS IN A BIOCIDALLY ACTIVE STATE VANSON HALOSOURCE, INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288066-A1 PHENOXY ACETIC ACID DERIVATIVES HRH2, HRH1, HRH3 LMNA 4243/4885SMN1; SMN2 4361/4885GAA 722/4885
US-20120283237-A1 NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS CIAPIN1, CLSPN, MRPL21 LMNA 3599/4885SMN1; SMN2 3782/4885GAA 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.